Equities analysts expect Teligent Inc (NASDAQ:TLGT) to post $19.80 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Teligent’s earnings. The highest sales estimate is $20.50 million and the lowest is $19.10 million. Teligent reported sales of $13.66 million during the same quarter last year, which indicates a positive year over year growth rate of 44.9%. The firm is expected to report its next earnings report on Monday, November 5th.

On average, analysts expect that Teligent will report full-year sales of $72.86 million for the current financial year, with estimates ranging from $72.03 million to $74.05 million. For the next year, analysts anticipate that the company will post sales of $98.70 million per share, with estimates ranging from $90.90 million to $106.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Teligent.

Teligent (NASDAQ:TLGT) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.18). Teligent had a negative net margin of 62.19% and a negative return on equity of 50.85%. The business had revenue of $16.75 million during the quarter, compared to analyst estimates of $16.06 million.

Several brokerages have commented on TLGT. Canaccord Genuity set a $4.00 price objective on shares of Teligent and gave the company a “hold” rating in a research report on Monday, August 13th. ValuEngine upgraded shares of Teligent from a “hold” rating to a “buy” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research upgraded shares of Teligent from a “sell” rating to a “hold” rating in a research report on Friday, June 22nd.

In other Teligent news, CEO Jason Grenfell-Gardner sold 52,800 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $4.00, for a total transaction of $211,200.00. Following the sale, the chief executive officer now owns 94,949 shares of the company’s stock, valued at $379,796. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 22.80% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in Teligent by 225.7% in the first quarter. JPMorgan Chase & Co. now owns 33,731 shares of the company’s stock valued at $274,000 after buying an additional 23,376 shares during the period. Guggenheim Capital LLC raised its holdings in shares of Teligent by 8.7% during the first quarter. Guggenheim Capital LLC now owns 383,466 shares of the company’s stock valued at $1,288,000 after purchasing an additional 30,532 shares during the period. BlackRock Inc. raised its holdings in shares of Teligent by 1.2% during the second quarter. BlackRock Inc. now owns 3,447,407 shares of the company’s stock valued at $11,928,000 after purchasing an additional 40,310 shares during the period. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Teligent by 83.9% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 94,443 shares of the company’s stock valued at $327,000 after purchasing an additional 43,091 shares during the period. Finally, Spark Investment Management LLC acquired a new position in shares of Teligent during the first quarter valued at about $162,000. 68.72% of the stock is currently owned by institutional investors.

TLGT traded up $0.01 during trading on Friday, hitting $3.82. 150,284 shares of the stock traded hands, compared to its average volume of 582,515. Teligent has a twelve month low of $2.43 and a twelve month high of $7.34. The company has a market cap of $204.51 million, a P/E ratio of -20.00 and a beta of 1.09. The company has a debt-to-equity ratio of 3.31, a current ratio of 2.77 and a quick ratio of 1.79.

About Teligent

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Featured Story: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.